Drug – bio-affecting and body treating compositions – Plant material or plant extract of undetermined constitution...
Reexamination Certificate
2005-09-06
2005-09-06
Coe, Susan D. (Department: 1654)
Drug, bio-affecting and body treating compositions
Plant material or plant extract of undetermined constitution...
C424S773000, C424S775000
Reexamination Certificate
active
06939570
ABSTRACT:
A pharmaceutical agent for treating an amyloid disease such as Alzheimer's Disease that includes a therapeutically effective amount of an extract obtained from the inner bark or root tissue of a plant of the genusUncaria,speciestomentosa,wherein the weight percentage of plant extract in the agent is in the range of from about 70% to about 95%.
REFERENCES:
patent: 4844901 (1989-07-01), Keplinger et al.
patent: 4940725 (1990-07-01), Keplinger et al.
patent: 5166139 (1992-11-01), Bombardelli et al.
patent: 5302611 (1994-04-01), Keplinger et al.
patent: 6039949 (2000-03-01), Pero
patent: 6264994 (2001-07-01), Castillo et al.
Stuppner et al., Chromatographia, vol. 34, No. 11/12, pp. 597-600, Dec. 1992.
Braquet et al. “Ethnopharmacology and the Development of Natural PAF Antagonists as Therapeutic Agents,” Journal of Ethnopharmacology, vol. 32, pp. 135-139, 1991.
Ho et al. “Phytochemicals in Teas and Rosemary and Their Cancer-Preventive Properties,” ACS Symp. Ser. (Food Phytochemicals for Cancer Prevention II) vol. 547, pp. 2-19 1994.
Jain et al. “Antiinflammatory Effects of an Ayurvedic Preparation,Brahmi rasayan, in Rodents,” Indian Journal of Experimental Biology, vol. 32, pp. 633-636, Sep. 1994.
Benson et al. “Serum Amyloid a Protein in Amyloidosis, Rheumatic, and Neoplastic Diseases,,” Arthritis and Rheumatism, vol. 22, No. 1, pp. 36-42, Jan. 1979.
Kamei et al. “Amyloidosis Associated with Juvenile Rheumatoid Arthritis,” Acta Pathol. Jpn., vol. 32, No. 1, pp. 23-33, 1982.
McAdam et al. “Association of Amyloidosis with Erythema Nodosum Leprosum Reactions and Recurrent Neutrophil Leucocytosis in Leprosy,” The Lancet, pp. 572-576, Sep. 27, 1975.
Metaxis et al. “Familial Mediterranean Fever and Amyloidosis,” Kidney International, vol. 20, pp. 676-685, 1981.
Harada et al. “Human Amyloid Protein: Chemical Variability and Homogeneity,” Journal of Histochemistry and Cytochemistry, vol. 19, No. 1, pp. 1-15, 1971.
Johnson et al. “Islet Amyloid, Islet-Amyloid Polypeptide, and Diabetes Mellitus,” The New England Journal of Medicine, vol. 321, No. 8, pp. 513-518, Aug. 24, 1989.
Johnson et al. “Islet Amyloid Polypeptide: Mechanisms of Amyloidogenesis in the Pancreatic Islet and Potential Roles in Diabetes Mellitus,” Laboratory Investigation, vol. 66, No. 5, pp. 522-534, 1992.
Gejyo et al. “A New Form of Protein Associated with Chronic Hemodialysis was Identified as B2 Metroglobulin,” Biochemical and Biophysical Research Communications, vol. 129, No. 3, pp. 701-706, 1985.
Gejyo et al. “B2-Metroglobulin: A New Form of Protein Associated with Chronic Hemodialysis,” Kidney International, vol. 30, pp. 385-390, Jan. 1986.
Skinner et al. “The Prealbinum Nature of the Amyloid Protein in Familial Amyloid Polyneuropathy (FAP)-Swedish Variety,” Biochemical and Biophysical Research Communications, vol. 99, No. 4, pp. 1326-1332, Apr. 1981.
Saraiva et al. “Studies on Plasma Transthyretin (Prealbinum) in Familial Amyloidotic Polyneropathy, Portugese Type,” Department of Medicine, Columbia University College of Physicians and Surgeons, vol. 102, No. 4, pp. 590-603, Jun. 1983.
Saraiva et al. “Amyloid Fibral Protein in Familial Amyloidotic Polyneurotherapy, Portugese Type,” The Amerivan Society for Clinical Investigation, Inc., vol. 74, pp. 104-119, Jul. 1984.
Tawara et al. “Amyloid Fibril Protein in Type 1 Familial Amyloidotic Polyneurotherapy in Japanese,” Laboratory of Clinical Investigation, vol. 98, No. 6, pp. 811-822, Dec. 1981.
“Progress Report on Alzheimers Disease,” The National Institute on Aging, National Institutes of Health, 1997, [author and complete publishing data unknown].
Cutler et al. “Correspondence: Tacrine in Alzheimers Disease,” The New England Journal of Medicine, pp. 808-810, Mar. 1993.
Barner et al. “Donepezil Use in Alzheimer Disease,” The Annals of Pharmacotherapy, vol. 32, pp. 70-77, Jan. 1998.
Glenner et al. “Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein,” Biochemical and Biophysical Research Communications, vol. 120, No. 3, pp. 885-890, May 16, 1984.
Masters et al. “Amyloid Plaque Core Protein in Alzheimers Disease and Down Syndrome,” Medical Sciences, vol. 82, pp. 4245-4249, Jun. 1983.
Husby et al. “Nomenclature of Amyloid and Amyloidosis,” Bulletin of the World Health Organization, vol. 71, No. 1, pp. 105-108, 1993.
Tanzi et al. “Protein Inhibitor Domain Encoded by an Amyloid Protein Precursor mRNA Associated with Alzheimer's Disease,” Nature, vol. 331, pp. 528-532, Feb. 1988.
Kitaguchi et al. “Novel Precursor of Alzheimer's Disease Amyloid Protein Shows Protease Inhibitory Activity,” Nature, vol. 331, pp. 530-532, Feb. 1988.
Ponte et al. “A New A4 Amyloid mRNA Contains a Domain Homologous to Serine Proteinase Inhibitors,” Nature, vol. 311, pp. 525-527, Feb. 1988.
Grundke-Iqbal et al. “Abnornal Phosphorylation of the Microtubule-Associated Protein Tau Alzheimer Cytoskeletal Pathology,” Proc. Natl. Acad. Sci. USA, vol. 83, pp. 4913-4917, Jul. 1986.
Kosik et al. “Microtubule—Associated Protein Tau is a Major Antigenic Component of Pairedd Helicule Filaments in Alzheimer's Disease,” Proc. Natl. Acad. Sci. USA, vol. 83 pp. 4044-4048, Jun. 1986.
Lee et al. “A68: A Major Subunit of Paired Helical Filaments and Derivatized Forms of Normal Tau,” Science, vol. 251, pp. 675-678, Feb. 1991.
Mandybur et al. “Cerebral Amyloid Angiopathy: The Vascular Pathology and Compolications,” Journal of Neuropathology and Experimental Neurology, vol. 45, No. 1, pp. 79-90, Jan. 1986.
Pardridge et al. “Amyloid Angiopathy of Alzheimer's Disease: Amino Acid Composition and Partial Sequence of a 4,200-Dalton Peptid Isolated from Cortical Microvessels,” Journal of Neurochemistry, vol. 49. No. 5, pp. 1394-1401, 1987.
Pike et al. “In Vitro Aging of B-Amyloid Protein Cause Peptide Aggregation and Neurotoxity,” Brain Research, vol. 563, pp. 311-314, 1991.
Pike et al. “Structure-Activity Analyses of B-Amyloid Peptides: Contributions of the B25-35 Region to Aggregation and Neurotoxicity,” Journal of Neurochemistry, vol. 64, No. 1, pp. 253-265, 1995.
Harrigan et al. “Beta Amyloid is Neurotoxic in Hippocampal Slice Cultures,” The Neurobiology of Aging, vol. 16, No. 5, pp 779-789, 1995.
Games et al. “Alzheimer-type neuopathology in transgenic mice overexpressing V717F B-amyloid precursor protein.” Nature, Vol 373, p. 523-527, Feb. 9, 1995.
Hsiao et al. “Age-related CNS Disorder and early death in transgenic FVB/N mice overexpressing alsheimer amyloid precursor proteins.” Neuron, vol. 15, 1203-1218, Nov., 1995.
Flood et al. “Amnestic effects in mice of four synthetic peptides homologous to amyloid B protein from patients wit alzheimer disease.” Proc. Natl. Acad. Sci. USA, vol. 88, pp. 3363-3366, Apr. 1991.
Flood et al. “An amyloid B-protein fragment, AB[12-18], equipotently impairs post-training memory processing when injected into different limbic system structures.” Brain Research 663 (1994).
Broeckhoven et al. “Amyloid B Protein precursor gene and Herediatary cerebral hemorrage with amyloidosis (Dutch).” Science, vol. 248, pp. 1120-1122.
Murrell et al. “A mutation in the amyloid recursor protein associated with hereditary alzheimer's disease.” Reports, pp. 97-99, Oct. 4, 1991.
Haass et al. “The swedish mutation causes early-onset alzheimer's disease by B-secretase cleavage with in the secretory pathway.” Nature medicine, vol. 1, No. 12, Dec. 1995.
Steinberg. “Uncaria Tomentosa (cat's Claw) A wondrous herb from the peruvian rain forest.” Townsend letter for doctors-pp, 44
Castillo Gerardo
Snow Alan
Coe Susan D.
Dwyer Patrick M.
University of Washington
LandOfFree
Composition and methods for treating Alzheimer's disease and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition and methods for treating Alzheimer's disease and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition and methods for treating Alzheimer's disease and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3440210